Tarsus Pharmaceuticals (TARS) Return on Capital Employed (2020 - 2026)

Tarsus Pharmaceuticals' Return on Capital Employed history runs 7 years deep, the most recent figure standing at 11.87% for Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 1910.0% year-over-year to 11.87% in Q1 2026; TTM through Mar 2026 was 11.87%, a 1910.0% increase from a year earlier, with the FY2025 full-year figure at 21.26%, up 2885.0% from the prior year.
• Return on Capital Employed climbed to 11.87% in Q1 2026 per TARS's latest filing, from 17.2% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 11.87% in Q1 2026 and bottomed at 62.25% in Q4 2023.
• The 5-year median for Return on Capital Employed is 30.96% (2025), against an average of 35.96%.
• Across the five-year window, Return on Capital Employed plunged 3331 bps in 2023 and surged 2789 bps in 2025, its largest moves.
• Year by year, Return on Capital Employed stood at 28.93% in 2022, then tumbled by 115 bps to 62.25% in 2023, then soared by 35 bps to 40.73% in 2024, then surged by 58 bps to 17.2% in 2025, then surged by 31 bps to 11.87% in 2026.
• Per Business Quant, the three latest TARS Return on Capital Employed figures stand at 11.87% (Q1 2026), 17.2% (Q4 2025), and 21.98% (Q3 2025).